Key Takeaways ADMA reported Q2 EPS of $0.15 and revenues of $122M, both beating consensus estimate.Asceniv drove 29% Y/Y underlying revenue growth, aided by strong adoption and proprietary tech.ADMA reaffirmed 2025+ guidance and sees $1.1B+ revenue potential before 2030 from plasma products.ADMA Biologics ((ADMA) reported better-than-expected results for the second quarter. Adjusted earnings per share of 15 cents beat the Zacks Consensus Estimate by a penny.Revenues of $122 million (up 14% year over year) a ...